ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/bispecific-PD-L1/VEGFA-antibody
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/bispecific-PD-L1/VEGFA-antibody
13
trial(s) found.
NCT07293351
Advanced
Phase 1 / Phase 2
Not yet recruiting
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (
CA266-0008
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
anti-CTLA4 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Clear cell renal cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07291076
Advanced
Phase 1 / Phase 2
Not yet recruiting
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (
CA266-0006
)
anti-CTLA4 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4560 - Nambour - Nambour General Hospital
NCT07221357
Advanced
Phase 2 / Phase 3
Recruiting
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (
CA266-0003
)
anti-VEGF monoclonal antibody
bispecific PD-L1/VEGFA antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07221149
Advanced
Phase 2 / Phase 3
Not yet recruiting
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (
CA266-0004
)
anti-PD-1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Oesophageal adenocarcinoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07147348
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-human, Open-label, Dose Escalation and Indication Expansion Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (
BNT3212-01
)
bispecific PD-L1/VEGFA antibody
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
Itraconazole
Pumitamig
SMO inhibitor
bispecific PD-L1/VEGFA antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,SMO-targeting
cancer therapy,VEGFA-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGFA-targeting
+ bispecific PD-L1/VEGFA antibody
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06953089
Advanced
Phase 2
Recruiting
A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors (
DB-1311-201
)
anti-B7H3 antibody-drug conjugate
anti-Trop2 antibody-drug conjugate
bispecific PD-L1/VEGFA antibody
Solid tumour
NSW
2060 - North Sydney - Mater Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06892548
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer (
BNT324-01
)
anti-B7H3 antibody-drug conjugate
bispecific PD-L1/VEGFA antibody
Lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
NCT06841055
Advanced
Phase 2
Recruiting
A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell Lung Cancer (NSCLC) Following Chemoimmunotherapy (
BNT327-07
)
bispecific PD-L1/VEGFA antibody
taxane
Non-small cell lung cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Hollywood Private Hospital
NCT06712355
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (
BNT327-03
)
anti-PD-L1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06712316
Advanced
Phase 2 / Phase 3
Recruiting
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer (
BNT327-06
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
2830 - Dubbo - Dubbo Base Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
NCT06618287
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors (
CA244-0001
)
bispecific EGFR/ERBB3 antibody
+ bispecific PD-L1/VEGFA antibody
Breast cancer
Lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06449222
Advanced
Phase 2
Recruiting
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer (
BNT327-02
)
bispecific PD-L1/VEGFA antibody
Breast cancer
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital (WITHDRAWN)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (WITHDRAWN)
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (10)
Not yet recruiting (3)
Recruitment Country and State
NSW (10)
QLD (9)
VIC (9)
SA (7)
WA (4)
Phase
Phase 1 / Phase 2 (6)
Phase 2 (3)
Phase 2 / Phase 3 (3)
Phase 3 (1)
Trial Type
Advanced (13)
Cancer Therapy Class
PD-1/PD-L1
100%
PD-L1
100%
VEGFA
100%
PD-1
31%
CTLA4
15%
VEGF
15%
B7H3
15%
AXL
8%
KIT
8%
MET
8%
RET
8%
ROS1
8%
VEGFR
8%
VEGFR2
8%
SMO
8%
Trop2
8%
EGFR
8%
ERBB3
8%
Facility
3021 - St Albans - Western Health - Sunshine Hospital (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
4575 - Birtinya - Sunshine Coast University Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2170 - Liverpool - Liverpool Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
2060 - North Sydney - Mater Hospital (2)
2500 - Wollongong - Cancer Care Wollongong (2)
4870 - Cairns - Cairns Base Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2109 - North Ryde - Macquarie University Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
4560 - Nambour - Nambour General Hospital (1)
3066 - Epping - Northern Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
3168 - Clayton - Monash Medical Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
4215 - Southport - Tasman Oncology (1)
6009 - Nedlands - One Clinical Research (1)
4217 - Benowa - Pindara Private Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2830 - Dubbo - Dubbo Base Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Respiratory tract cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Non-small cell lung cancer
Breast cancer
Clear cell renal cell carcinoma
Kidney cancer
Urogenital cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Colorectal cancer
Lower gastrointestinal cancer
Gastroesophageal cancer
Oesophageal adenocarcinoma
Oesophageal cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Breast adenocarcinoma
Triple-negative breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy